Posters
Glomerular Diseases: Genetics to Therapeutics
October 22, 2026 | 10:00 AM - 12:00 PM
Location: Exhibit Hall A, Convention Center
Session Description
Poster Session
Posters
PLIN5 Overexpression Remodels Lipid Droplet-Mitochondria Contacts and Confers Mild Protection from Kidney Injury in Alport Syndrome
Temporal Changes in the Prognostic Value of Proteinuria in Alport Syndrome Mouse Models
Identification of Functional Minicollagen EMB-9 Constructs in Caenorhabditis elegans for Adeno-Associated Virus-Based Gene Therapy Approaches to Alport Syndrome
COL4A3-Associated Alport Spectrum Disease Misdiagnosed as Primary FSGS After Pregnancy-Related Proteinuria: Diagnostic Delay from Limited Biopsy
Autophagy Activation in Alport Syndrome Is Insufficient to Mitigate Podocyte Lipotoxicity and Mitochondrial Dysfunction
Apolipoprotein C-III Deficiency Mediates Podocyte Lipotoxicity in Glomerular Diseases
ADAMTS13 Preserves Kidney Function in Alport Syndrome
New Antibody Tools to Study Alport Syndrome
Reversal of Diabetic Nephropathy and FSGS by GFR Criteria Using Recombinant Mutated Human Angiopoietin-Like 4 (Protein 8520), a First-in-Class Biological Drug Candidate, to Induce Repair
Altered Lipid Handling and Cytoskeletal Dynamics in RCAN1-Associated Nephrotic Syndrome
SERCA-Mediated Calcium Homeostasis Regulates Slit Diaphragm Integrity, Autophagy, and Nephrocyte Function
Urinary Endoplasmic Reticulum (ER) Chaperones: Biomarkers of Glomerular ER Stress
ERK1/2 Phosphorylation Drives Podocyte Injury Across Diverse Kidney Diseases
BNIP3 Couples Mitophagy to Extracellular Vesicle Biogenesis in Diabetic Kidney Disease
Disease-Induced Alterations in Albumin Structure and Factor Binding Correlate with Recurrence of FSGS After Kidney Transplantation
Collapsing Glomerulopathy Associated with Diffuse Large B-Cell Lymphoma Causing Nephrotic Syndrome and AKI
Proteinuria Reduction in Nephrotic Syndrome Is Associated with Threshold-Dependent Lipoprotein Changes
Small Molecule Inhibition of TRPC5 Ameliorates Disease Progression in Murine Model of Alport Syndrome
Role of OSBPL7 in Lipid-Mediated Glomerular Injury and Senescence in Alport Syndrome
Effect of SGLT2 Inhibitors on Crescentic Glomerulonephritis
Engineered Podocyte-Targeted Extracellular Vesicle Therapy: A New Strategy for CKD
Arterial Lesions in Primary Podocytopathies in Young Adults Are Associated with Glomerular Vascular Endothelial Growth Factor Expression and Poorer Kidney Outcomes
Mineralocorticoid Receptor Antagonism and Glucagon-Like Peptide 1 Receptor Agonism Have Direct Effects on Glomerular Cells to Reduce Glomerular Albumin Permeability in Diabetes
Role of the Post-Translational ISGylation of IRF9 in Diabetes-Induced Podocyte Injury
Reprogramming Podocyte (PODO) Senescence Through SGLT2 Inhibition in Diabetic Nephropathy (DN)
BMPR2 Deficiency Aggravates Podocyte Injury via Aberrant TGF-β/DACH1 Signaling in Diabetic Kidney Disease
GLS1 Deficiency Drives RIPK1-Mediated Podocyte PANoptosis in Diabetic Kidney Disease
Therapeutic Efficacy of Cysteamine Bitartrate in Mouse Model of IgAN
Extrarenal Detection of DNAJB9 in the Setting of Endoplasmic Reticulum Stress Supports a Two-Hit Model for Fibrillary Glomerulonephritis
RBP-J Functions as a Transcriptional Repressor of HIV-LTR in Podocytes and Protects Against HIV-Associated CKD
Renal-Protective Effects of Praliciguat in Preclinical Models of FSGS
HTRA1 Deficiency Worsens Adriamycin-Induced Glomerulosclerosis in a Mouse Model
Targeting mTORC1/S6K1/rpS6 Phosphorylation Prevents Podocyte Hypertrophy and FSGS Lesion Formation
Clinically Relevant Polo-Like Kinase Inhibitors to Preserve Podocyte Structural Integrity During Injury
Optimization of the Adriamycin Mouse Model to Improve Translational Evaluation of Podocytopathy Therapies
Autophagy-Dependent, Podocyte-Specific AMPK Activation Preserves Glomerular Survival
Activation of Integrin α3β1 Restores Podocyte Function and Reduces Injury in FSGS Mouse Models
Dynein-Facilitated Biosynthetic Sorting of Nephrin to the Ubiquitin-Proteasome System: A Targetable Pathway for Diabetic Podocytopathy
A Novel ANLN Variant (p.Lys491Asn) with Incomplete Penetrance: Expanding the Phenotypic Spectrum to Minimal Change Disease in an Indian Pedigree
The Spontaneously Hypercholesterolemic (SHC) Rat as a Translational Model of FSGS: Renoprotective Effects of Irbesartan
Circulating β-Amyloid Disrupts Podocyte α3β1 Integrin Adhesion in FSGS
Differential Temporal Profiles of Urinary Sediment Podocyte mRNAs Distinguish Minimal Change Disease from FSGS
The Nonsteroidogenic Panmelanocortin Receptor Agonist (Nle4, D-Phe7)-α-Melanocyte-Stimulating Hormone Ameliorates THSD7A-Associated Membranous Nephropathy in an Active Immunization Mouse Model
Soluble Guanylate Cyclase Activator plus SGLT2 Inhibition Preserves Podocytes and Reduces Inflammation in Experimental Diabetic Nephropathy
WIPF3 Controls Podocyte Foot Process Architecture in a Murine Albuminuria Model
miR-125b Inhibition Uncouples Inflammation from Blood Pressure: A Sex-Specific Mechanism of Glomerular Injury